Respiratory syncytial virus (RSV) is the most common cause of hospitalizations in children under the age of 1. To date, there is no effective treatment for established RSV infections, only methods for prevention. In this research, the authors developed an inhaled anti‐RSV treatment that showed efficacy in mice, rats, and a neonatal lamb model of RSV infection, significantly reducing viral load and pathology compared to placebo‐treated animals.
All Keywords
【저자키워드】 monoclonal antibody, respiratory syncytial virus, RSV, nebulization, mAb nebulization,
【저자키워드】 monoclonal antibody, respiratory syncytial virus, RSV, nebulization, mAb nebulization,